NASDAQ:ADAG Adagene Q4 2025 Earnings Results & Report $2.46 -0.28 (-10.22%) Closing price 04:00 PM EasternExtended Trading$2.46 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Adagene beat analyst earnings expectations but missed on revenue in its Q4 2025 results, released April 1, 2026. The company reported EPS of -$0.0440 versus the -$0.28 consensus estimate, while revenue of $3.84 million fell short of the $17.50 million estimate by $13.66 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateApril 1, 2026TimeBefore Market OpensConference Call7:00 AM ET Adagene EPS ResultsActual EPS-$0.0440Consensus EPS -$0.28Beat/MissBeat by +$0.2360One Year Ago EPSN/AAdagene Revenue ResultsActual Revenue$3.84 millionExpected Revenue$17.50 millionBeat/MissMissed by -$13.66 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (6-K)Annual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(20-F) Adagene Q4 2025 Earnings FAQ Did Adagene beat earnings estimates for Q4 2025? Adagene (NASDAQ:ADAG) reported earnings of -$0.0440 per share for Q4 2025, beating the consensus estimate of -$0.28. The report was announced on Wednesday, April 1, 2026. What was Adagene's revenue for Q4 2025? Adagene reported revenue of $3.84 million for Q4 2025, against a consensus estimate of $17.50 million. Adagene Earnings HeadlinesAdagene Inc. Sponsored ADR (NASDAQ:ADAG) Stock Has Consensus Price Target of $8.67 According to BrokeragesOctober 9, 2026 | americanbankingnews.comAdagene Inc. Announces Resignation of Chunfang Gu as Executive Director of Finance, Effective September 30, 2026September 26, 2026 | marketscreener.comMYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 13 at 1:00 AM | Profits Run (Ad)Adagene Inc. Announces NMPA Clearance Of Investigational New Drug Application For ADG138, A Novel HER2xCD3 Double-Masked Bispecific T-Cell EngagerSeptember 24, 2026 | marketscreener.comMAdagene Inc. meldet NMPA-Zulassung des Antrags auf klinische Prüfung (IND) für ADG138, einen neuartigen doppelt maskierten bispezifischen HER2xCD3-T-Zell-EngagerSeptember 23, 2026 | de.marketscreener.comDAdagene Gains NMPA Clearance On Phase 1 For ADG138 In Solid Tumors, Set To Begin In Q4 '26September 22, 2026 | rttnews.comSee More Adagene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adagene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adagene and other key companies, straight to your email. Email Address About AdageneAdagene (NASDAQ:ADAG) Inc. is a biotechnology company focused on discovering and developing novel antibody-based cancer immunotherapies. The company combines computational methods, antibody engineering and translational research to create medicines designed to address limitations associated with conventional immuno-oncology treatments. Adagene’s technology platform includes NEObody, which is intended to identify antibodies with differentiated binding characteristics, and SAFEbody, a masking technology designed to conditionally activate antibodies in the tumor microenvironment. These platforms support the company’s efforts to develop therapies directed at immune-regulatory targets, including programs involving checkpoint and costimulatory pathways. Founded in 2017, Adagene has operated with a research and development presence in both the United States and China, serving the global biopharmaceutical market. The company was co-founded and led by Peter Luo, who has served as chief executive officer. Its work has included internal drug development as well as collaborations intended to advance antibody therapeutics.View Adagene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
